Diseases of the central nervous system (CNS) are on the rise all around the globe. The therapeutic medicines now in use to treat CNS diseases have a significant level of efficacy. However, these medications' inability to pass the blood–brain barrier, as well as the invasiveness of the technology used to enable localized drug delivery in disease, limit their use. -parts of the brain have thwarted painless and comprehensive CNS disease treatment. Neurological diseases cannot be treated with a coherent approach. These disorders, like all chronic diseases, are a complicated metabolic system involving the interaction of a patient's genes with their unique environment. As a result, precise and reliable testing procedures, such as patient biomarkers, age, and genetic history, are required.